<p>STAAR Surgical（纳斯达克代码：STAA - 获取免费报告）于周三发布了季度财报。这家医疗器械供应商报告本季度每股收益为 0.17 美元，低于分析师一致预期的 0.18 美元，差距为 0.01 美元，Briefing.com 报道。STAAR Surgical 的股本回报率为-16.11%，净利润率为-42.45%。该公司本季度的收入为 9470 万美元，而分析师预期为 9215 万美元。去年同期，该公司每股收益为 0.20 美元。</p>
<p>获取 <strong>STAAR Surgical</strong> 警报：</p>
<h2>STAAR Surgical 股票表现</h2>
<ul>
<li>内部人士显著增持的前四只股票</li>
</ul>
<p>周五中午，STAA 股票下跌 0.63 美元，报 25.90 美元。该公司交易了 633,128 股，低于其平均交易量 1,183,428 股。该公司的市值为 12.8 亿美元，市盈率为-13.42，贝塔值为 0.82。STAAR Surgical 的 52 周低点为 13.50 美元，52 周高点为 32.00 美元。该公司的 50 日简单移动平均线为 26.96 美元，200 日简单移动平均线为 21.88 美元。</p>
<h2>对 STAAR Surgical 的对冲基金看法</h2>
<p>对冲基金最近买入和卖出了该公司的股票。Soleus Capital Management L.P.在第二季度增持了 STAAR Surgical 的股份，增幅为 16.5%。Soleus Capital Management L.P.目前拥有 2,984,733 股该医疗器械供应商的股票，价值 50,084,000 美元，此前在该期间内又购买了 421,840 股。美国银行在第二季度增持了 STAAR Surgical 的股份，增幅为 17.1%。美国银行目前拥有 1,153,895 股该医疗器械供应商的股票，价值 19,362,000 美元，此前在该期间内又购买了 168,285 股。高盛集团在第一季度增持了 STAAR Surgical 的股份，增幅为 33.4%。高盛集团目前拥有 544,843 股该医疗器械供应商的股票，价值 9,606,000 美元，此前在该期间内又收购了 136,390 股。Federated Hermes Inc.在第二季度新建了 STAAR Surgical 的股份，价值 6,095,000 美元。最后，法国巴黎银行金融市场在第二季度增持了 STAAR Surgical 的股份，增幅为 322.4%。法国巴黎银行金融市场目前拥有 243,470 股该医疗器械供应商的股票，价值 4,085,000 美元，此前在该期间内又购买了 185,836 股。目前 96.70% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级上调和下调</h2>
<ul>
<li>随着 2024 年美国前景改善，Star Surgical 表现出色</li>
</ul>
<p>几位研究分析师对该公司发表了看法。Piper Sandler 在周一的报告中重申了对 STAAR Surgical 股票的 “中性” 评级。Canaccord Genuity Group 在 10 月 21 日的研究报告中重新发布了 “持有” 评级，并设定了 28.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 STAAR Surgical 股票的 “卖出（d）” 评级。Stifel Nicolaus 在 8 月 7 日的研究报告中设定了 STAAR Surgical 股票的 28.00 美元价格目标，并给予该股票 “持有” 评级。最后，瑞穗证券在 7 月 16 日的报告中将 STAAR Surgical 的目标价从 17.00 美元上调至 18.00 美元，并给予该公司 “中性” 评级。十位股票研究分析师对该股票给予了 “持有” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “减持”，共识目标价为 20.67 美元。</p>
<p><strong>查看我们对 STAAR Surgical 的最新股票分析</strong></p>
<h2>STAAR Surgical 公司简介</h2>
<p>（获取免费报告）</p>
<p>STAAR Surgical 公司及其子公司设计、开发、制造、营销和销售用于眼睛的植入式镜片及其伴随的输送系统，以将镜片送入眼睛。该公司提供植入式 Collamer 镜片产品系列（ICLs），用于治疗视觉障碍，如近视、远视、散光和老花眼。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 STAAR Surgical</li>
<li>如何做空纳斯达克：易于遵循的指南</li>
<li>Equinix 股票尽管下调收入指引仍上涨</li>
<li>期权交易 - 理解行使价格</li>
<li>MongoDB：这不是骗局，这个 AI 项目是个好消息</li>
<li>投资 5G 技术的顶级股票</li>
<li>140 亿美元的日本工厂标志着台积电的大胆 AI 战略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 STAAR Surgical 吗？</h2>
<p>在考虑 STAAR Surgical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 STAAR Surgical 并不在名单上。</p>
<p>虽然 STAAR Surgical 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

达视光学

<p>STAAR Surgical（纳斯达克代码：STAA）报告的季度每股收益为 0.17 美元，低于预期的 0.18 美元。该公司的收入为 9470 万美元，超过了 9215 万美元的预期。STAAR Surgical 的股本回报率为负 16.11%，净利润率为 42.45%。股票交易价格下跌至 25.90 美元，市值为 12.8 亿美元。分析师的评级意见不一，普遍评级为 “减持”，目标价格为 20.67 美元。机构投资者持有该股票的 96.70%</p>

<p>STAAR Surgical (NASDAQ:STAA - Get Free Report) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01), Briefing.com reports. STAAR Surgical had a negative return on equity of 16.11% and a negative net margin of 42.45%.The company had revenue of $94.70 million during the quarter, compared to analyst estimates of $92.15 million. During the same period last year, the firm earned $0.20 earnings per share.</p>
<div class="lb-trans"><p>STAAR Surgical（纳斯达克代码：STAA - 获取免费报告）于周三发布了季度财报。这家医疗器械供应商报告本季度每股收益为 0.17 美元，低于分析师一致预期的 0.18 美元，差距为 0.01 美元，Briefing.com 报道。STAAR Surgical 的股本回报率为-16.11%，净利润率为-42.45%。该公司本季度的收入为 9470 万美元，而分析师预期为 9215 万美元。去年同期，该公司每股收益为 0.20 美元。</p>
</div><p>Get <strong>STAAR Surgical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>STAAR Surgical</strong> 警报：</p>
</div><h2>STAAR Surgical Stock Performance</h2>
<div class="lb-trans"><h2>STAAR Surgical 股票表现</h2>
</div><ul>
<li>Top 4 Stocks With Notable Insider Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>内部人士显著增持的前四只股票</li>
</ul>
</div><p>Shares of STAA stock traded down $0.63 during mid-day trading on Friday, reaching $25.90. 633,128 shares of the company were exchanged, compared to its average volume of 1,183,428. The company has a market capitalization of $1.28 billion, a P/E ratio of -13.42 and a beta of 0.82. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $32.00. The business's 50 day simple moving average is $26.96 and its 200 day simple moving average is $21.88.</p>
<div class="lb-trans"><p>周五中午，STAA 股票下跌 0.63 美元，报 25.90 美元。该公司交易了 633,128 股，低于其平均交易量 1,183,428 股。该公司的市值为 12.8 亿美元，市盈率为-13.42，贝塔值为 0.82。STAAR Surgical 的 52 周低点为 13.50 美元，52 周高点为 32.00 美元。该公司的 50 日简单移动平均线为 26.96 美元，200 日简单移动平均线为 21.88 美元。</p>
</div><h2>Hedge Funds Weigh In On STAAR Surgical</h2>
<div class="lb-trans"><h2>对 STAAR Surgical 的对冲基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. Soleus Capital Management L.P. boosted its holdings in STAAR Surgical by 16.5% in the second quarter. Soleus Capital Management L.P. now owns 2,984,733 shares of the medical instruments supplier's stock worth $50,084,000 after purchasing an additional 421,840 shares during the period. Bank of America Corp DE boosted its position in STAAR Surgical by 17.1% during the 2nd quarter. Bank of America Corp DE now owns 1,153,895 shares of the medical instruments supplier's stock valued at $19,362,000 after purchasing an additional 168,285 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of STAAR Surgical by 33.4% during the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier's stock valued at $9,606,000 after acquiring an additional 136,390 shares during the period. Federated Hermes Inc. acquired a new position in shares of STAAR Surgical during the second quarter valued at $6,095,000. Finally, BNP Paribas Financial Markets boosted its stake in STAAR Surgical by 322.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 243,470 shares of the medical instruments supplier's stock valued at $4,085,000 after purchasing an additional 185,836 shares during the period. 96.70% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金最近买入和卖出了该公司的股票。Soleus Capital Management L.P.在第二季度增持了 STAAR Surgical 的股份，增幅为 16.5%。Soleus Capital Management L.P.目前拥有 2,984,733 股该医疗器械供应商的股票，价值 50,084,000 美元，此前在该期间内又购买了 421,840 股。美国银行在第二季度增持了 STAAR Surgical 的股份，增幅为 17.1%。美国银行目前拥有 1,153,895 股该医疗器械供应商的股票，价值 19,362,000 美元，此前在该期间内又购买了 168,285 股。高盛集团在第一季度增持了 STAAR Surgical 的股份，增幅为 33.4%。高盛集团目前拥有 544,843 股该医疗器械供应商的股票，价值 9,606,000 美元，此前在该期间内又收购了 136,390 股。Federated Hermes Inc.在第二季度新建了 STAAR Surgical 的股份，价值 6,095,000 美元。最后，法国巴黎银行金融市场在第二季度增持了 STAAR Surgical 的股份，增幅为 322.4%。法国巴黎银行金融市场目前拥有 243,470 股该医疗器械供应商的股票，价值 4,085,000 美元，此前在该期间内又购买了 185,836 股。目前 96.70% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><ul>
<li>Star Surgical Shines as U.S. Outlook Improves for 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>随着 2024 年美国前景改善，Star Surgical 表现出色</li>
</ul>
</div><p>Several research analysts have weighed in on the company. Piper Sandler reiterated a &#34;neutral&#34; rating on shares of STAAR Surgical in a report on Monday. Canaccord Genuity Group reissued a &#34;hold&#34; rating and set a $28.00 target price on shares of STAAR Surgical in a research report on Tuesday, October 21st. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of STAAR Surgical in a research report on Wednesday, October 8th. Stifel Nicolaus set a $28.00 price objective on shares of STAAR Surgical and gave the stock a &#34;hold&#34; rating in a research report on Thursday, August 7th. Finally, Mizuho increased their price target on STAAR Surgical from $17.00 to $18.00 and gave the company a &#34;neutral&#34; rating in a report on Wednesday, July 16th. Ten equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of &#34;Reduce&#34; and a consensus price target of $20.67.</p>
<div class="lb-trans"><p>几位研究分析师对该公司发表了看法。Piper Sandler 在周一的报告中重申了对 STAAR Surgical 股票的 “中性” 评级。Canaccord Genuity Group 在 10 月 21 日的研究报告中重新发布了 “持有” 评级，并设定了 28.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 STAAR Surgical 股票的 “卖出（d）” 评级。Stifel Nicolaus 在 8 月 7 日的研究报告中设定了 STAAR Surgical 股票的 28.00 美元价格目标，并给予该股票 “持有” 评级。最后，瑞穗证券在 7 月 16 日的报告中将 STAAR Surgical 的目标价从 17.00 美元上调至 18.00 美元，并给予该公司 “中性” 评级。十位股票研究分析师对该股票给予了 “持有” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “减持”，共识目标价为 20.67 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on STAAR Surgical</strong></p>
<div class="lb-trans"><p><strong>查看我们对 STAAR Surgical 的最新股票分析</strong></p>
</div><h2>STAAR Surgical Company Profile</h2>
<div class="lb-trans"><h2>STAAR Surgical 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.</p>
<div class="lb-trans"><p>STAAR Surgical 公司及其子公司设计、开发、制造、营销和销售用于眼睛的植入式镜片及其伴随的输送系统，以将镜片送入眼睛。该公司提供植入式 Collamer 镜片产品系列（ICLs），用于治疗视觉障碍，如近视、远视、散光和老花眼。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than STAAR Surgical</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>Equinix Stock Rises Despite Lower Revenue Guidance</li>
<li>Options Trading - Understanding Strike Price</li>
<li>MongoDB: It’s No Trick, This AI Play Is a Treat</li>
<li>Top Stocks Investing in 5G Technology</li>
<li>$14B Japanese Facility Signals TSMC's Bold AI Strategy</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 STAAR Surgical</li>
<li>如何做空纳斯达克：易于遵循的指南</li>
<li>Equinix 股票尽管下调收入指引仍上涨</li>
<li>期权交易 - 理解行使价格</li>
<li>MongoDB：这不是骗局，这个 AI 项目是个好消息</li>
<li>投资 5G 技术的顶级股票</li>
<li>140 亿美元的日本工厂标志着台积电的大胆 AI 战略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=STAA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in STAAR Surgical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 STAAR Surgical 吗？</h2>
</div><p>Before you consider STAAR Surgical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 STAAR Surgical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 STAAR Surgical 并不在名单上。</p>
</div><p>While STAAR Surgical currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 STAAR Surgical 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

达视光学（NASDAQ:STAA）公布财报结果